LIBERUM: Aptamer* - CEO leaving

LIBERUM: Aptamer* - Deals slow to convert

LIBERUM: UK Small & Mid Cap Dispatches

LIBERUM: Morning Comment

LIBERUM: Aptamer* - Seeds sown, green shoots emerging

LIBERUM: UK Small & Mid Cap Dispatches: Tech & Media 2023 Outlook, Model Portfolios February 2023, AAA publisher results, Aptamer, FirstGroup, Market Highlights

LIBERUM: Aptamer* - Right place, wrong price

LIBERUM: Aptamer* - Conditions curtail H1 performance

LIBERUM: Aptamer* - Statement shows momentum building

LIBERUM: Aptamer* - Prelims supports growth projections

LIBERUM: Aptamer* - Update shows revenue acceleration

LIBERUM: UK Small & Mid Cap Dispatches

LIBERUM: Morning Comment

LIBERUM: Aptamer* - Strong debut at H1 results

LIBERUM: Aptamer* - Initiation - Build better binders

Cambridge Nutritional Sciences - Operational improvements set to drive future gr

Cambridge Nutritional Science’s (CNS) FY 2024 results make for encouraging reading, from both a financial and operational perspective, that should provide investors with confidence around management’s ability to execute on its long-term growth strategy, in our view. Underpinning our positive sentiment is the payback which is now being realised from the group’s manufacturing excellence programmes which have delivered significant growth in the gross margin in FY 2024, increasing 1,488 bps to 61.9%

PANMURE LIBERUM: Inspiration Healthcare: Inspiration catches a break

Morning Note – 25 July 2024

Hybridan Small Cap Feast - 25 July 24

* A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to continue to make

On the mend

Shield Therapeutics - AOP Milestone Monetisation gives comfort on cash position

STX has done a deal with its major shareholder, AOP Health International Management, under which it will get a $5.7m cash advance, to be paid back by the future milestone payment ($11.4m) that STX expects to receive upon the approval of Accrufer in China in 2026. Although the payback terms are favourable to AOP, we would not expect it to further invest if it did not have a clear line of sight to payback via the China approval, and more broadly STX’s ability to become profitable. In today’s relea